In the last couple of years, a record number of personalized therapeutic products were approved in the US, establishing an urgent need for companion diagnostics and causing many drug developers to actively seek external support and expertise

... Read more

Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contract service providers

Roots Analysis is pleased to announce the ... Read more

The numerous benefits offered by prefilled syringes, coupled to the growing self-medication trend, have led to the approval of a number of drugs in combination with such devices, resulting in an increase in need to outsource fill / finish operations

... Read more

Roots Analysis has announced the addition of “Biopharma Contract Manufacturing Market (3^rd ... Read more

Owing to the ever-increasing number of start-ups that are involved in R&D of novel biologics, there is an enormous opportunity for the CMOs in this domain. It is worth emphasizing that, since 2000, more than 115 new CMOs have been established in order to serve to the growing demand for novel ... Read more

Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages

Roots Analysis is pleased to ... Read more

Roots Analysishas announced the addition of “Biopharma Contract Manufacturing Market (3 ... Read more

... Read more

The success of CTLA4, PD-1, and PD-L1 inhibitors paved the way for researchers to explore the vast therapeutic potential of immune checkpoint modulation, enabling the discovery of product candidates against clinical conditions beyond oncology

... Read more